Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dexcom Gains Approval For No-Calibration, 'Interoperable' CGM System

Executive Summary

US FDA's March 27 de novo clearance of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for diabetics gives Dexcom a no-calibration offering, a first-in-class "interoperable" system and sets out a streamlined regulatory pathway for future CGM devices with similar features.


Related Content

2018 US Device Approvals: The Year Of De Novos And Digital Health
Good News For Senseonics, Medtronic Diabetes Devices
US Device Approvals: Q1 Snapshot
Global Device Approvals, Weekly Snapshot: March 26-April 1, 2018
FDA Advisory Panel Says 'Yes' To Senseonics' Eversense 90-Day CGM Device
Bigfoot Biomedical Raised $55m, Including Backing From Abbott
Abbott 'No-Fingerstick' CGM System For Diabetes Wins Medicare Coverage
Abbott Gains Go-Ahead For First 'No-Fingerstick' CGM


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts